RATIONALE: Food allergic patients report poorer quality of life (QoL) than patients with diabetes. Peanut allergy (PA) is one of the most common and persistent food allergies. AR101, an investigational oral immunotherapy for PA, was studied in PALISADE, a randomized, double-blind, placebo-controlled phase 3 trial in patients aged 4-55. It is the largest study conducted to date evaluating an investigational treatment for patients with PA, providing an opportunity to assess baseline QoL of patients in a well characterized PA population. METHODS: At screening, subjects (self-report) and parents/caregivers (proxy-report) completed an age-appropriate Food Allergy QoL Questionnaire (FAQLQ). Domain and total scores for subjects aged > _8 and parents/caregivers of subjects 4-17-years-old (yo) were calculated (scale range: 1-7; higher scores indicate worse QoL) and relationships to demographic and disease history variables were evaluated. RESULTS: 367 PA subjects and 442 parents/caregivers completed baseline assessments. Worse PA-related QoL was seen with increasing age (4-6yo, 7-12yo, teens) across all FAQLQ domains reported by parents/ caregivers and on 2 of 3 domains reported by subjects (8-12yo, 13-17yo, adults). The Emotional Impact (EI) domain had the highest score among subjects (4.80), followed by Allergen Avoidance and Dietary Restrictions (4.40) and Risk of Accidental Exposure (4.20). In contrast, Food Anxiety (4.23) had the highest score among parents/caregivers, followed by Social and Dietary Limitations (4.17) and EI (3.82). Differences in score patterns by demographic and disease history variables were also seen. CONCLUSIONS: PALISADE subjects represent a well characterized peanut-allergic population whose scores reflect the significant impact to QoL associated with peanut allergy. RATIONALE: IgE to a-Gal is causal in delayed anaphylaxis to mammalian meat and relates to bites from hard ticks. Though it is unclear whether ticks intrinsically express a-gal, these glycans have been shown to be present in tick saliva. Because gram-negative enteric bacteria are known to express a-Gal, we considered the possibility that the source of a-Gal relates to symbionts in lone star ticks. Of the lone star tick symbionts known to overlap the distribution of a-Gal cases [i.e. Rickettsiae spotted fever group(SFG) and Ehrlichia chaffeensis], Rickettsia amblyommii, which only causes a mild clinical syndrome, is most prevalent. To explore this hypothesis we sought to assess seroprevalance to Rickettsiae SFG and Ehrlichia in subjects sensitized to a-Gal. METHODS: Sera from 369 subjects in central Virginia were available from a large observational study designed to investigate IgE sensitization to a-Gal. IgG to Rickettsiae SFG and Ehrlichia chaffeensis were assayed by commercially available ELISA and micro-immunofluorescence kits, respectively. RESULTS: 280 subjects were positive for IgE to a-Gal (76%). Of these, 21% (59/280) were positive for IgG to Rickettsia. In the 89 subjects not sensitized to a-Gal, 15% (13/89) were positive for IgG to Rickettsia. In preliminary investigation we have observed similar results in the Ehrlichia assays. CONCLUSIONS: Seroprevalence to Rickettsia trends higher (p50.18) in subjects sensitized to a-Gal but nonetheless is absent in nearly 80% of cases. Although the tests used may not be sufficiently sensitive to identify subclinical exposure, the current data do not support a link between tickborne bacteria and a-Gal sensitization.
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A population-based study of FPIES prevalence among US children University of Southern California, Los Angeles, CA, 6 Northwestern University Feinberg School of Medicine, Chicago, IL. RATIONALE: Food protein-induced enterocolitis syndrome (FPIES) is considered to be a rare non-IgE, cell-mediated food allergy (FA). In recent years, interest in FPIES increased considerably but estimates of FPIES prevalence in the USA are lacking. METHODS: A population-based survey was administered online or via telephone to a nationally representative sample of USA households. Prevalence estimates were based on responses from NORC at the University of Chicagos nationally-representative, probability-based AmeriSpeak Panel (51% completion rate), which were augmented by non-probability-based responses via calibration weighting to increase precision. Prevalence was estimated via weighted proportions. RESULTS: Survey was administered between October 2015 and September 2016; parent-proxy responses were collected for 38,408 children. Overall, physician-diagnosed FPIES was reported for 0.5% (95% CI; 0.4-0.6) of the population under the age 18 years, in response to a question asking about the presence of the following physician-diagnosed allergic conditions: FPIES, eosinophilic esophagitis (EoE), asthma, atopic dermatitis/eczema, hay fever/allergic rhinitis/seasonal allergies. Among children with parent-reported FPIES (n5261), 65.3% (55.2-74.2) had > _1 parent-reported-IgE-FA (meeting stringent symptoms-report criteria for reaction), 5.9% (2.8-12.1) reported EoE, 25.2% (18.5-33.4) physician-diagnosed asthma, 9.6% (5.8-15.5) atopic dermatitis/eczema, and 32.59% (24.4-41.9%) seasonal allergies. Thirteen families (4.9%) reported multiple children with FPIES; 5 children (1.9%) had a parent (in all cases a father) with FPIES. CONCLUSIONS: In this first nationally representative sample of US households, physician-diagnosed FPIES was reported for 0.5% of children younger than 18 years, suggesting a higher prevalence than previous estimates. Children with FPIES had high rates of other allergic conditions including IgE-FA, EoE, asthma, and seasonal allergies.
